Published in BMC Cancer on December 16, 2014
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | NCT01353222
Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer (VESPER) | NCT01812369
Neoadjuvant Erlotinib (Tarceva) in Transitional Cell Carcinoma | NCT00749892
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC | NCT00859339
Sunitinib in Treating Patients With Locally Advanced Bladder Cancer | NCT00526656
Safety Study on AdCD40L Gene Therapy for Bladder Cancer | NCT00891748
Vaccine Therapy in Treating Patients With Transitional Cell Cancer of the Bladder | NCT00070070
Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy | NCT01827618
Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer | NCT01734798
Combination Chemotherapy in Treating Patients With Bladder Cancer | NCT00003701
Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium | NCT00082719
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw (2016) 0.85
Performance of simultaneous high temporal resolution quantitative perfusion imaging of bladder tumors and conventional multi-phase urography using a novel free-breathing continuously acquired radial compressed-sensing MRI sequence. Magn Reson Imaging (2015) 0.79
Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact? Bladder Cancer (2016) 0.75
CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer. Oncogene (2016) 0.75
Protein Profiling of Bladder Urothelial Cell Carcinoma. PLoS One (2016) 0.75
Author'S reply. Cent European J Urol (2015) 0.75
Role of downregulated miR-133a-3p expression in bladder cancer: a bioinformatics study. Onco Targets Ther (2017) 0.75
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature (2014) 8.48
International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol (2011) 5.95
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell (2014) 5.52
EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol (2013) 4.58
Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol (2005) 4.57
The present and future burden of urinary bladder cancer in the world. World J Urol (2009) 4.56
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol (2011) 3.59
Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol (2013) 2.83
Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol (2005) 2.58
mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev (2013) 2.53
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol (2012) 2.31
Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol (2004) 2.14
Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int (2006) 1.85
The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol (1991) 1.81
Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology (2013) 1.71
A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol (1996) 1.69
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol (2011) 1.51
Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol (2006) 1.42
Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol (2004) 1.28
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer (2012) 1.22
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun (2003) 1.19
AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial. Clin Cancer Res (2010) 1.15
Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res (2011) 1.15
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res (2009) 1.14
Phase II study of everolimus in metastatic urothelial cancer. BJU Int (2013) 1.07
Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer. Jpn J Clin Oncol (2011) 1.05
Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res (2011) 1.03
Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study. Int J Clin Oncol (2012) 1.02
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urol Oncol (2014) 0.99
A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int (2010) 0.99
Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother (2008) 0.98
Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol (2008) 0.96
Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. J Urol (2013) 0.90
Adjuvant chemotherapy in lymph node positive bladder cancer. Urol Oncol (2008) 0.87
Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer. Biomed Pharmacother (2012) 0.87
A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder. Urology (2013) 0.87
Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. Urol Oncol (2012) 0.87
A phase II trial of temsirolimus in second-line metastatic urothelial cancer. Med Oncol (2012) 0.85
CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. Expert Rev Vaccines (2011) 0.85
Neoadjuvant chemotherapy with gemcitabine plus carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer. Int J Urol (2013) 0.84
A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett (2012) 0.83
Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced bladder cancer: a study by the Hellenic Cooperative Oncology Group. J Urol (2004) 0.78
Perioperative Chemotherapy in Advanced Bladder Cancer - Part II: Adjuvant Treatment. Onkologie (2003) 0.77
Efficacy of radical cystectomy plus adjuvant intraarterial chemotherapy with gemcitabine and cisplatin on locally advanced bladder cancer. Chin Med J (Engl) (2014) 0.77
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48
Randomized controlled trial of collaborative care management of depression among low-income patients with cancer. J Clin Oncol (2008) 2.47
Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A (2003) 2.31
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol (2003) 1.96
Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol (2006) 1.92
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res (2003) 1.81
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol (2012) 1.76
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol (2011) 1.75
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology (2010) 1.65
Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU Int (2009) 1.60
EphB4 expression and biological significance in prostate cancer. Cancer Res (2005) 1.53
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol (2012) 1.37
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res (2010) 1.37
Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol (2002) 1.28
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs (2009) 1.26
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer (2007) 1.23
Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol (2009) 1.21
Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med (2012) 1.19
Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Clin Genitourin Cancer (2005) 1.15
Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem (2009) 1.14
Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol (2004) 1.11
One-year follow-up of collaborative depression care for low-income, predominantly Hispanic patients with cancer. Psychiatr Serv (2011) 1.11
Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases. Radiology (2015) 1.10
Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int (2011) 1.08
Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene (2003) 1.06
Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol (2004) 1.03
Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst (2006) 1.03
Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med (2013) 1.02
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res (2003) 1.02
Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev (2013) 0.98
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol (2006) 0.97
Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol (2008) 0.96
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Target Oncol (2014) 0.96
Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy. Eur J Cancer (2005) 0.93
Targeted therapy in renal cancer. Ther Adv Med Oncol (2009) 0.92
Improving treatment of depression among low-income patients with cancer: the design of the ADAPt-C study. Gen Hosp Psychiatry (2007) 0.92
Cabazitaxel in prostate cancer: stretching a string. Lancet (2010) 0.92
Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol (2011) 0.91
Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer (2003) 0.91
Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol Cancer Ther (2012) 0.91
Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer (2004) 0.90
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer (2014) 0.90
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res (2006) 0.90
The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. Prostate (2010) 0.89
Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer (2004) 0.89
Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Rev Anticancer Ther (2005) 0.88
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol (2007) 0.87
Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. Mol Cancer Ther (2005) 0.87
The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. Urol Clin North Am (2005) 0.86
A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. Invest New Drugs (2013) 0.86
Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer (2009) 0.86
Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer. Urology (2006) 0.86
Hospice staff perspectives on Dignity Therapy. J Palliat Med (2013) 0.84
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst (2014) 0.83
Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. J Cancer Res Clin Oncol (2007) 0.82
Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas (2011) 0.82
Targeted α-particle therapy of bone metastases in prostate cancer. Clin Nucl Med (2013) 0.82
Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol (2006) 0.82
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer (2014) 0.82
A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int (2008) 0.81
Tivozanib in the treatment of renal cell carcinoma. Biologics (2013) 0.80
Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer (2006) 0.79
Immune response to sipuleucel-T in prostate cancer. Cancers (Basel) (2012) 0.79
A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma. Int J Clin Oncol (2011) 0.79
Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. World J Urol (2008) 0.78
Small cell bladder cancer: biology and management. Semin Oncol (2012) 0.78
Pain management, supportive and palliative care in patients with renal cell carcinoma. BJU Int (2007) 0.78
FDG PET/CT demonstration of pancreatic metastasis from prostate cancer. Clin Nucl Med (2011) 0.78
Blood cells and their use in active immunotherapy of prostate cancer. Hum Vaccin Immunother (2012) 0.77
Ethnic differences in neuroendocrine cell expression in normal human prostatic tissue. Urology (2005) 0.77
Molecular prognostic factors in bladder cancer. BJU Int (2005) 0.77
Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemother Pharmacol (2014) 0.76
Perioperative chemotherapy for urothelial cancer: how have we made a "sow's ear" out of a chemotherapy-sensitive tumor? Cancer (2009) 0.75
The future in advanced prostate cancer: take your partners or is the last dance for me? Rev Urol (2004) 0.75
COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER. Ther Adv Med Oncol (2009) 0.75
Novel tyrosine kinase inhibitors for renal cell carcinoma. Expert Rev Clin Pharmacol (2013) 0.75
The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol (2011) 0.75
Salvage chemotherapy for refractory germ cell tumors. Oncology (Williston Park) (2014) 0.75
Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clin Genitourin Cancer (2013) 0.75
Hitting Prostate Cancer Where It Hurts: Maximizing Control of Osseous Metastases. Oncology (Williston Park) (2015) 0.75
Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU Int (2008) 0.75
Liquid-crystal tunable color filters based on aluminum metasurfaces. Opt Express (2017) 0.75
Light guiding, bending, and splitting via local modification of interfaces of a photonic waveguide. Opt Lett (2019) 0.75